Stock Scorecard

Stock Summary for Lipella Pharmaceuticals Inc (LIPO) - $2.72 as of 3/28/2025 12:57:10 AM EST

Total Score

13 out of 30

Safety Score

7 out of 100

Currently on the following lists
Small Cap Stock List
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for LIPO

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LIPO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LIPO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LIPO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LIPO (7 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 1
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 1
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for LIPO

Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes - Lipella Pharmaceuticals ( NASDAQ:LIPO ) 2/11/2025 3:52:00 PM
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus 2/11/2025 10:46:00 AM
Dow Dips 150 Points; Bristol Myers Squibb Issues Weak Outlook - American Superconductor ( NASDAQ:AMSC ) , Digital Turbine ( NASDAQ:APPS ) 2/6/2025 5:08:00 PM
Dow Edges Higher; US Weekly Jobless Claims Increase - Digital Turbine ( NASDAQ:APPS ) , Avinger ( NASDAQ:AVGR ) 2/6/2025 3:06:00 PM
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus 2/6/2025 11:00:00 AM
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement - Lipella Pharmaceuticals ( NASDAQ:LIPO ) 1/10/2025 6:24:00 PM
Spartan Capital Securities, LLC Caps Off a Remarkable Year with Key December Transactions - 1847 Holdings ( AMEX:EFSH ) , Lipella Pharmaceuticals ( NASDAQ:LIPO ) 12/31/2024 4:55:00 PM
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement - Lipella Pharmaceuticals ( NASDAQ:LIPO ) 12/18/2024 7:28:00 PM
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group - Lipella Pharmaceuticals ( NASDAQ:LIPO ) 11/21/2024 10:30:00 AM
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group 11/21/2024 10:30:00 AM

Financial Details for LIPO

Company Overview
Ticker LIPO
Company Name Lipella Pharmaceuticals Inc
Country USA
Description N/A
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2024
Next Earnings Date N/A

Stock Price History
Last Day Price 2.72
Price 4 Years Ago 0.00
Last Day Price Updated 3/28/2025 12:57:10 AM EST
Last Day Volume 13,447
Average Daily Volume 93,333
52-Week High 7.75
52-Week Low 2.02
Last Price to 52 Week Low 34.65%

Valuation Measures
Trailing PE N/A
Industry PE 37.01
Sector PE 40.10
5-Year Average PE -1.59
Free Cash Flow Ratio 2.43
Industry Free Cash Flow Ratio 11.91
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 2.97
Total Cash Per Share 1.12
Book Value Per Share Most Recent Quarter 1.79
Price to Book Ratio 4.54
Industry Price to Book Ratio 8.86
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 13.18
Industry Price to Sales Ratio Twelve Trailing Months 88.85
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics
Total Shares Outstanding 1,209,000
Market Capitalization 3,288,480
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -77.81%
Reported EPS 12 Trailing Months -4.88
Reported EPS Past Year -2.44
Reported EPS Prior Year -5.02
Net Income Twelve Trailing Months -4,263,476
Net Income Past Year -4,618,965
Net Income Prior Year -2,597,692
Quarterly Revenue Growth YOY 27.90%
5-Year Revenue Growth 144.15%
Operating Margin Twelve Trailing Months -698.00%

Balance Sheet
Total Cash Most Recent Quarter 1,353,734
Total Cash Past Year 3,293,738
Total Cash Prior Year 5,121,743
Net Cash Position Most Recent Quarter 1,353,734
Net Cash Position Past Year 3,268,738
Long Term Debt Past Year 25,000
Long Term Debt Prior Year 25,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 0.99
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 3,144,448
Total Stockholder Equity Prior Year 4,675,596
Total Stockholder Equity Most Recent Quarter 1,458,918

Free Cash Flow
Free Cash Flow Twelve Trailing Months -18,107,610
Free Cash Flow Per Share Twelve Trailing Months -14.98
Free Cash Flow Past Year -3,164,606
Free Cash Flow Prior Year 0

Options
Put/Call Ratio 0.00
Has Options False
Liquidity Rating None

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.14
MACD Signal -0.21
20-Day Bollinger Lower Band 2.09
20-Day Bollinger Middle Band 2.83
20-Day Bollinger Upper Band 3.57
Beta 0.00
RSI 48.32
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System
Modified 3/28/2025 12:57:56 AM EST